Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.

Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.

Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
J0-14
Québec, Québec
Canada G1S 4L8
julie.lemieux@crchudequeb...

Latest news

56 entries « ‹ 1 of 6 › »

Audet S, Doyle C, Lemieux C, Tardif MA, Gauvreau A, Simonyan D, Nabi H, Lemieux J

Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015

Journal Article

Curr Oncol, 30 (2), 2023.

Abstract | Links:

Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial

Journal Article

JACC Cardiovasc Imaging, 16 (3), 2023.

Abstract | Links:

Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

Journal Article

JAMA, 327 (20), 2022.

Abstract | Links:

Simmons C, Rayson D, Joy AA, Henning JW, Lemieux J, McArthur H, Card PB, Dent R, Brezden-Masley C

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Journal Article

Ther Adv Med Oncol, 14 , 2022.

Abstract | Links:

Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J,

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Journal Article

Eur J Cancer, 152 , 2021.

Abstract | Links:

Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32

Journal Article

J Natl Cancer Inst, 113 (2), 2021.

Abstract | Links:

Morin-Buote J, Ennour-Idrissi K, Poirier É, Lemieux J, Furrer D, Burguin A, Durocher F, Diorio C

Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Gagnet S, Diorio C, Provencher L, Mbuya-Bienge C, Lapointe J, Morin C, Lemieux J, Nabi H

Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Roy V, Ruel S, Ivers H, Savard MH, Gouin JP, Caplette-Gingras A, Lemieux J, Couture F, Savard J

Stress-buffering effect of social support on immunity and infectious risk during chemotherapy for breast cancer

Journal Article

Brain Behav Immun Health, 10 , 2021.

Abstract | Links:

Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Gelmon KA, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson AM, Rea DW, Stambolic V

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Journal Article

JNCI Cancer Spectr, 5 (5), 2021.

Abstract | Links:

56 entries « ‹ 1 of 6 › »
Signaler des ajouts ou des modifications

Active projects

  • Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, from 2019-10-01 to 2024-09-30
  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
  • PALbociclib CoLlaborative Adjuvant Study (PALLAS study), from 2017-05-17 to 2025-12-25
  • Perfectionism and psychosocial adjustment to cancer : A mixed methods study, from 2020-03-31 to 2024-03-31
  • Projet pilote de l'utilisation d'une application pour le suivi et la prise en charge des effets secondaires associés aux traitements anti-néoplasiques oraux chez les patientes avec cancer du sein, from 2021-08-01 to 2023-07-31
  • TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
  • The effect of cannabinoid receptors on breast cancer survival, from 2022-09-01 to 2024-08-31
  • Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2023-03-31

Recently finished projects

  • MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., from 1997-04-01 to 2021-03-31
  • Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08
Data provided by the Université Laval research projects registery